Moffitt Notice of Blackbaud Data Incident. Learn More
Clinical Trials Search
Clinical Trial 20162
Cancer Type: Cutaneous
Study Type: Treatment
NCT#: NCT04160065
Phase: Phase I
Prinicipal Investigator: Andrew Brohl
Study Title
Phase 1 Trial of Intralesional Immunotherapy with IFx-Hu2.0 Vaccine in Patients with Advanced Merkel Cell Carcinoma or Cutaneous Squamous Cell Carcinoma
Summary
This is primarily a safety study that is designed to evaluate IFx-Hu2.0 monotherapy and provide foundational evidence to potentially support further studies investigating IFx-Hu2.0 + anti-PD-1 combination therapy for patients with advanced MCC or cSCC.
Objective
Primary Objective The primary objective is to assess the safety of vaccinating patients with advanced MCC or cSCC with intralesional IFx-Hu2.0. Secondary Objective Secondary objectives are to assess the feasibility of IFx-Hu2.0 administration and evaluate any preliminary efficacy in patients with advanced MCC or cSCC.
Therapies
Medications
IFx-Hu2.0 ()
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.